Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ISAAC LEVY

NPI
1871577221
CMS profile
312330
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$4,929.44

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,529.35 188
Long term medical supply or device loan $299.10 3
Education $100.99 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ISAAC LEVY

NPI 1871577221 · CMS profile ID 312330

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871577221?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ISAAC LEVY, NPI 1871577221, CMS profile ID 312330. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871577221?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ISAAC LEVY, NPI 1871577221, CMS profile ID 312330. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871577221?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ISAAC LEVY, NPI 1871577221, CMS profile ID 312330, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1871577221?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $4,929.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $24.9406/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226041108 CMS
Stemline Therapeutics Inc. $21.7905/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244094127 CMS
Exelixis Inc. $15.8105/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218795153 CMS
SERVIER PHARMACEUTICALS LLC $20.4405/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229099379 CMS
PFIZER INC. $18.3605/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229154743 CMS
PFIZER INC. $21.8005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229119599 CMS
Janssen Biotech, Inc. $24.5405/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175101839 CMS
Lilly USA, LLC $18.0005/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186570186 CMS
Geron Corporation $26.4705/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238890648 CMS
Janssen Biotech, Inc. $1.0105/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175099852 CMS
Janssen Biotech, Inc. $1.0105/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175101215 CMS
Janssen Biotech, Inc. $10.8505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175102157 CMS
AstraZeneca Pharmaceuticals LP $31.8905/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215351914 CMS
GENZYME CORPORATION $35.9605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233284961 CMS
PFIZER INC. $13.9505/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229212837 CMS
Agios Pharmaceuticals, Inc. $23.9505/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253249224 CMS
Caris MPI, Inc. $20.8705/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234282448 CMS
Merck Sharp & Dohme LLC $20.3005/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238135809 CMS
Daiichi Sankyo Inc. $29.9305/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197068491 CMS
E.R. Squibb & Sons, L.L.C. $14.3204/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184927192 CMS
Novartis Pharmaceuticals Corporation $23.1904/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200687180 CMS
Myriad Genetic Laboratories, Inc. $27.6804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245407240 CMS
PFIZER INC. $26.5004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228939048 CMS
AstraZeneca Pharmaceuticals LP $15.8204/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214796474 CMS
Novartis Pharmaceuticals Corporation $23.6704/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200687172 CMS
GENZYME CORPORATION $31.2804/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233284953 CMS
E.R. Squibb & Sons, L.L.C. $14.2704/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184927176 CMS
PFIZER INC. $19.9304/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228943465 CMS
ARRAY BIOPHARMA INC $24.3304/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228945932 CMS
SOBI, INC $85.0004/11/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1240280368 CMS
Merck Sharp & Dohme LLC $27.8404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238180221 CMS
Novartis Pharmaceuticals Corporation $17.7304/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200687176 CMS
Eisai Inc. $23.3904/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244483484 CMS
Lilly USA, LLC $14.2204/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186640711 CMS
Merck Sharp & Dohme LLC $26.5204/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238040815 CMS
Novartis Pharmaceuticals Corporation $22.2304/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200687178 CMS
AstraZeneca Pharmaceuticals LP $21.2604/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214803727 CMS
GlaxoSmithKline, LLC. $26.0703/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191743099 CMS
PFIZER INC. $26.7503/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228913891 CMS
GlaxoSmithKline, LLC. $15.7003/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191187490 CMS
AstraZeneca Pharmaceuticals LP $16.4103/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214773001 CMS
AstraZeneca Pharmaceuticals LP $17.4803/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215341566 CMS
Celgene Corporation $19.6303/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184927170 CMS
Daiichi Sankyo Inc. $29.5203/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197052167 CMS
AstraZeneca Pharmaceuticals LP $31.9303/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215338949 CMS
Janssen Biotech, Inc. $12.3003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175100250 CMS
Alexion Pharmaceuticals, Inc. $26.4603/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211398512 CMS
AstraZeneca Pharmaceuticals LP $15.8203/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214800873 CMS
Merck Sharp & Dohme LLC $15.1603/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238090121 CMS
PFIZER INC. $28.8303/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228914507 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,870.38 182
PY2020 $4,394.75 158
PY2021 $7,365.04 184
PY2022 $7,991.97 193
PY2023 $5,942.90 209
PY2024 $15,269.47 235
PY2025 $4,929.44 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $14,203.00 1
PY2025 Principal investigator $754,791.33 11
PY2024 Principal investigator $285,056.92 11
PY2023 Recipient $725.51 1
PY2023 Principal investigator $171,602.12 12
PY2022 Recipient $23.00 1
PY2022 Principal investigator $642,217.99 20
PY2021 Recipient $609.00 1
PY2021 Principal investigator $340,384.50 22
PY2020 Recipient $10.86 1
PY2020 Principal investigator $558,222.57 17
PY2019 Recipient $1,731.80 2
PY2019 Principal investigator $525,658.72 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $176,853.69 12/18/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC ISAAC LEVY MD PA
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study No dispute reported 06/30/2026 1190311521
Principal investigator 1 GENZYME CORPORATION $22,534.00 12/12/2025 Non-covered Recipient Entity
Millennium Oncology Research Clinic Inc
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226108213
Principal investigator 1 Karyopharm Therapeutics Inc. $3,114.00 11/12/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664190
Principal investigator 1 Karyopharm Therapeutics Inc. $7,782.00 09/26/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664188
Principal investigator 1 SANOFI US SERVICES INC. $650.00 07/11/2025 Non-covered Recipient Entity
Millennium Oncology Research Clinic Inc
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226097751
Principal investigator 1 Karyopharm Therapeutics Inc. $7,782.00 06/16/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664184
Principal investigator 1 Amgen Inc. $11,478.80 06/01/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246644721
Recipient GENZYME CORPORATION $14,203.00 04/28/2025 Covered Recipient Physician A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226102328
Principal investigator 1 Karyopharm Therapeutics Inc. $16,712.00 03/31/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664186
Principal investigator 1 Novartis Pharmaceuticals Corporation $494,845.04 03/31/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC ISAAC LEVY MD PA
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study No dispute reported 06/30/2026 1190311523
Principal investigator 1 Eli Lilly and Company $12,112.00 02/11/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC DBA ISAAC LEVY
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187884646
Principal investigator 1 Eli Lilly and Company $927.80 01/09/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC DBA ISAAC LEVY
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187885508